China Universal CNI BIOMEDICINE ETF(159839) rises 0.97%, aiming for a third consecutive gain

NewTimeSpace (newtimespace.com) News, as of 14:04 on June 23, 2026, China Universal Biopharmaceutical ETF (159839) rose 0.97%, aiming for a third consecutive gain. The latest price was 0.31 yuan. Over a longer time frame, as of June 22, 2026, the ETF accumulated a gain of 1.31% over the past week, ranking 1/3 among comparable funds.

In terms of liquidity, China Universal Biopharmaceutical ETF recorded an intraday turnover rate of 6.59% and a trading volume of 70.1563 million yuan. Over a longer time frame, as of June 22, the ETF's average daily trading volume over the past week reached 47.6222 million yuan.

In terms of scale, the latest scale of China Universal Biopharmaceutical ETF reached 1.043 billion yuan, hitting a one-year high. (Data source: Wind)

In terms of capital flows, the latest net inflow for China Universal Biopharmaceutical ETF was 23.0870 million yuan. Over a longer time frame, within the past 15 trading days, there were 13 days of net inflow, attracting a total of 114 million yuan, with an average daily net inflow of 7.6052 million yuan. (Data source: Wind)

Data shows that leveraged funds are continuously positioning. The latest margin financing purchase amount of China Universal Biopharmaceutical ETF reached 6.3593 million yuan, with the latest margin financing balance standing at 54.4328 million yuan. (Data source: Wind)

From the perspective of return capability, as of June 22, 2026, since its inception, China Universal Biopharmaceutical ETF achieved a highest single-month return of 27.69%, a longest streak of consecutive up months of 5 months, a maximum cumulative gain during that streak of 31.17%, and an average return of 5.77% in up months. As of June 22, 2026, the ETF's annualized excess return over its benchmark for the past three months was 1.38%.

In terms of drawdown, as of June 22, 2026, China Universal Biopharmaceutical ETF recorded a drawdown of 0.23% relative to its benchmark since the beginning of the year.

In terms of fees, China Universal Biopharmaceutical ETF has a management fee rate of 0.50% and a custodian fee rate of 0.10%, the lowest fee rates among comparable funds.

In terms of tracking accuracy, as of June 22, 2026, the three-month tracking error of China Universal Biopharmaceutical ETF was 0.050%, achieving the highest tracking accuracy among comparable funds.

It is worth noting that the valuation of the Guosen Biopharmaceutical Index, which the fund tracks, is at a historical low. The latest price-to-book (PB) ratio is 2.83x, which is lower than over 94.21% of the time in the past year, highlighting attractive valuation.

China Universal Biopharmaceutical ETF closely tracks the Guosen Biopharmaceutical Index. The Guosen Biopharmaceutical Index takes listed companies related to the biopharmaceutical industry on the Shanghai, Shenzhen, and Beijing stock exchanges as the sample space. Based on a comprehensive ranking of market capitalization and liquidity, it selects the top 30 securities as index constituents. It reflects the overall operation of the biopharmaceutical industry and provides market participants with index-based investment targets for the sub-industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.